Famous Patents
Felix Hoffmann, a German chemist, was searching for something to relieve his father's arthritis. In doing so, he "rediscovered" acetylsalicylic acid and in 1900, patented a stable process for developing it. Hence, we have aspirin.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178531 | Antiviral agents The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention o... | 05/15/2012 |
| 8163707 | 4′-allene-substituted nucleoside derivatives The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or ... | 04/24/2012 |
| 8124584 | Macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring s... | 02/28/2012 |
| 8119616 | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhance... | 02/21/2012 |
| 8101567 | Heteroaryl-containing tripeptide HCV serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS... | 01/24/2012 |
| 8030307 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4... | 10/04/2011 |
| 7994489 | Skin tanning and light therapy incorporating light emitting diodes The invention relates to a skin tanning chamber, the improvement comprising at least one light emitting diode emitting a UVA light, such as a UVA LED that emits essentially only UVA. Additionally, multiple LEDs of varying types with various characteristic wavelength... | 08/09/2011 |
| 7985819 | Styrene-maleic anhydride copolymers for bioapplications and their preparation The present invention discloses styrene-maleic anhydride copolymers preparations using solventless techniques. The solventless method resulted in reduced amounts of residues, such as unreacted styrene and/or maleic anhydride monomers, which makes the copolymers part... | 07/26/2011 |
| 7977347 | Quinazoline based EGFR inhibitors The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR... | 07/12/2011 |
| RE42375 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 05/17/2011 |
| 7928136 | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and dis... | 04/19/2011 |
| 7919627 | Processes for the preparation of hydroxylamines The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acce... | 04/05/2011 |
| 7910587 | Quinoxalinyl dipeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 03/22/2011 |
| 7910558 | Bridged macrocyclic compounds and processes for the preparation thereof The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent optionally in the presence of a... | 03/22/2011 |
| 7888361 | Tyrosine kinase inhibitors containing a zinc binding moiety The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. ... | 02/15/2011 |
| 7846938 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below. These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK... | 12/07/2010 |
| 7842813 | Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceuti... | 11/30/2010 |
| 7829551 | Method and composition for the control of arthropods The present invention relates to the use of certain siloxanes and mixtures thereof in the control of arthropods such as insects and arachnids, and in particular ectoparasites, such as head lice. ... | 11/09/2010 |
| 7718769 | Tri-peptide hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS... | 05/18/2010 |
| 7687459 | Arylalkoxyl hepatitis C virus protease inhibitors The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 03/30/2010 |
| 7662779 | Triazolyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 02/16/2010 |
| 7655160 | Compositions of matter: system II The present invention relates to new compositions of matter, particularly metals and alloys, and methods of making such compositions. The new compositions of matter exhibit long-range ordering and unique electronic character. ... | 02/02/2010 |
| 7635683 | Quinoxalinyl tripeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 12/22/2009 |
| 7622452 | C-9 alkenylidine bridged macrolides The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceuti... | 11/24/2009 |
| 7605126 | Acylaminoheteroaryl hepatitis C virus protease inhibitors The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV)... | 10/20/2009 |
| 7589067 | 6, 11-bridged tricyclic macrolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 09/15/2009 |
| 7582605 | Phosphorus-containing hepatitis C serine protease inhibitors The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A proteas... | 09/01/2009 |
| 7566719 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) ... | 07/28/2009 |
| 7563877 | Processes for the preparation of -(2-aminobenzo[]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]ox... | 07/21/2009 |
| 7547781 | Quinazoline based EGFR inhibitors containing a zinc binding moiety The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related d... | 06/16/2009 |
| 7538225 | Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acce... | 05/26/2009 |
| 7517859 | Spirocyclic bicyclolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 04/14/2009 |
| 7468419 | Cyclosporin derivatives for the treatment of immune disorders The present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof: wherein A is of the formula: | 12/23/2008 |
